Neil Graham
Director/Board Member at ASLAN PHARMACEUTICALS LIMITED
Net worth: - $ as of 31/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Carl Firth | M | 51 |
ASLAN Pharmaceuticals Pte Ltd.
 ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | 14 years |
| Adam Tomasi | M | 54 | 7 years | |
| Andrew Howden | M | 64 |
ASLAN Pharmaceuticals Pte Ltd.
ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | 8 years |
| Kiran Asarpota | M | 45 |
ASLAN Pharmaceuticals Pte Ltd.
ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | 14 years |
| Kathleen Metters | M | 66 |
ASLAN Pharmaceuticals Pte Ltd.
ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | 3 years |
| Robert Hoffman | M | 58 |
ASLAN Pharmaceuticals Pte Ltd.
ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | 6 years |
| Robert Lisicki | M | 57 | - | |
| Sandeep Kulkarni | M | 43 | 2 years | |
| Daniel Janney | M | 58 | 7 years | |
| Kimberly Ann Davis | F | 56 | 2 years | |
| Someit Sidhu | M | 34 | 2 years | |
| Robert Alexander | M | 54 | 7 years | |
| Arnout Ploos van Amstel | M | 58 | 1 years | |
| Parvinder Singh Thiara | M | 39 | 1 years | |
| Jennifer Jarrett | F | 53 | 1 years | |
| Bonnie Bassler | M | 61 | 8 years | |
| Michael Howell | M | 47 | 2 years | |
| Simon Green | M | - | 2 years | |
| Steven James | M | 66 | 8 years | |
| Jason Pitofsky | M | 47 | 7 years | |
| Eric Andersen | M | 62 | 16 years | |
| Huda Zoghbi | M | 69 | 8 years | |
| Joseph LaRosa | M | 65 | 13 years | |
| Harlan Radford | M | 54 | 3 years | |
| Christine Poon | F | 71 | 14 years | |
| Robert Andreatta | M | 62 | 6 years | |
| Amit Munshi | M | 56 | 1 years | |
| Paul Walker | M | 49 | 7 years | |
| N. Coles | M | 63 | 7 years | |
| Matthew Davis | M | - |
Tiziana Life Sciences Ltd. (United Kingdom)
 Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 2 years |
| Steven Schoch | M | 64 | 1 years | |
| Verender Badial | M | 51 | 1 years | |
| Kiran Nistala | M | 51 | 1 years | |
| Jana Baskar | M | - | 2 years | |
| Harjit Singh | M | - | - | |
| Marlyn Mathew | F | - | - | |
| Dave Brady | M | - | - | |
| Mark Volpe | M | - | 12 years | |
| Chin Lee | M | 54 | - | |
| Alexandre Kaoukhov | M | - | 2 years | |
| Mary Cromwell | M | - | - | |
| Gary Whale | M | 50 | 1 years | |
| Kerry K. Reinertsen | M | - | 13 years | |
| Theresa Lowry | F | 50 | - | |
| Ben Goodger | M | 61 | 8 years | |
| Alex Schwartz | M | - | 3 years | |
| Maya Bermingham | F | - | 9 years | |
| Alan Shuldiner | M | - | 10 years | |
| Nouhad Husseini | M | - | 13 years | |
| Sally A. Paull | F | - | 8 years | |
| Johnathan Lancaster | M | - | 5 years | |
| Stephen Doyle | M | 50 | 6 years | |
| E. Sutherland | M | 54 | 1 years | |
| Ned Braunstein | M | - | 15 years | |
| Dolca Thomas | M | 53 | 1 years | |
| Vesna Tosic | M | - | 6 years | |
| Marion McCourt | F | 64 | 6 years | |
| Hashan de Silva | M | - | 1 years | |
| Amy Ladd | M | 66 | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Eric M. Shooter | M | 100 | 26 years | |
| Murray Goldberg | M | 79 | 20 years | |
| Malcolm McComas | M | 68 | 20 years | |
| Robert Landry | M | 60 | 11 years | |
| David Weinreich | M | - | 7 years | |
| Preston Klassen | M | 55 | - | |
| Ferda Cevikbas | M | - | - | |
| William L. Delaat | M | 72 | 14 years | |
| Marc Tessier-Lavigne | M | 64 | 12 years | |
| Charles A. Baker | M | 91 | 29 years | |
| Thomas H. Adams | M | 81 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 1 years |
| Robert Alexander Ingram | M | 81 | 1 years | |
| BILL Kessler | M | 57 | 4 years | |
| Stuart A. Kolinski | M | 58 | 10 years | |
| Brett Charlton | M | 67 | 24 years | |
| Ching Feng Sun | M | 61 | 5 years | |
| Urvashi Rangan | M | - |
Johns Hopkins Bloomberg School of Public Health
| 5 years |
| Kevin Schutz | M | - |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 1 years |
| Carrie Brownstein | M | 54 | - | |
| Craig Paterson | M | 59 | 3 years | |
| Jim Tripp | M | 54 | 5 years | |
| Ke Andrew Yuan | M | - | 4 years | |
| Javier Cote-Sierra | M | 61 | - | |
| Phillip Gutry | M | 50 | 3 years | |
| Charlie Sanders | M | 91 |
Trimeris, Inc.
 Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 10 years |
| Ed Rayner | M | - | 2 years | |
| Jerry Wollman | M | - |
Johns Hopkins Bloomberg School of Public Health
| 1 years |
| Manisha A. Narasimhan | M | 48 | 7 years | |
| Christopher Cabell | M | 54 | - | |
| Michael Weiss | M | 58 | - | |
| Michael A. Recny | M | - |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 12 years |
| Pamela A. Trail | M | 68 | 7 years | |
| Lim Damien | M | 61 | 5 years | |
| Reza Fathi | M | 69 | 4 years | |
| Jay Markowitz | M | 61 | 3 years | |
| E. Gary Cook | M | 79 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 7 years |
| Jesper Gromada | M | - | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 72 | 75.00% |
| Singapore | 11 | 11.46% |
| Australia | 7 | 7.29% |
| Bermuda | 3 | 3.13% |
| Israel | 3 | 3.13% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Neil Graham
- Personal Network
